

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMME United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/723,981 11/26/2003		Rene Hoet	10280-062001 9492		
26161	7590	06/26/2006		EXAMINER	
FISH & RI	CHARDS	ON PC	LUCAS, ZACHARIAH		
P.O. BOX 10 MINNEAPO		55440-1022		ART UNIT	PAPER NUMBER
WINVERIC	Dio, mi	330 1022		1648	

DATE MAILED: 06/26/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

()		Application No.	Applicant(s)		
		10/723,981	HOET ET AL.		
Office Action Summary		Examiner	Art Unit		
		Zachariah Lucas	1648		
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover sheet with the c	orrespondence address		
A SH WHIC - Exter after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.15 SIX (6) MONTHS from the mailing date of this communication. Openiod for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONEI	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status					
1)⊠	Responsive to communication(s) filed on 26 N	ovember 2003.			
2a)[This action is FINAL . 2b)⊠ This	action is non-final.			
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.		
Dispositi	ion of Claims				
5) 6) 7)	Claim(s) <u>1-38</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-38</u> are subject to restriction and/or expressions.	wn from consideration.			
Applicati	ion Papers				
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine	epted or b) objected to by the Eddrawing(s) be held in abeyance. See tion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority u	ınder 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachmen					
2) Notic 3) Infor	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa			

Application/Control Number: 10/723,981

Art Unit: 1648

DETAILED ACTION

1. Claims 1-38 are pending in the application.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-22, 29, 31, 37, 38, drawn to phage particles and methods of producing such, classified in class 435, subclass 235.1.
 - II. Claims 23-28, 30, and 32-36, drawn to polynucleotides encoding a first chimeric phage coat protein and a second phage coat protein, classified in class 536, subclass 23.72.

The inventions are distinct, each from the other because of the following reasons:

3. The inventions of Group II and of claims 1-22, 37, and 38 of Group I are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case, the polynucleotides of Group II may be used in methods for the production of phage particles as claimed by Group I, or may be used in methods for the detection of analysis of test sample as a hybridization partner to the genomes of bound phage particles. Thus, the polynucleotides may be used in a materially different method from those of Group I, and are therefore distinct therefrom.

Application/Control Number: 10/723,981

Page 3

Art Unit: 1648

4. The inventions of Group II and of claims 29 and 31 of Group I are directed to related products. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, the polynucleotides of Group II encode the products of Group I. However, the polynucleotides have different designs (being composed of different types of molecules), and have different functions and modes of operation one from the other. The inventions are therefore distinct.

Species Election

5. This application contains claims directed to the following patentably distinct species:

For Group I above, the Applicant is further required to elect one from each of the following species groups:

Embodiments of the claimed invention wherein the sequence to be displayed A) varies among the host cells or B) is invariant among the host cells.

Embodiments of the claimed invention wherein the first condition for maintaining the host cells 1) increases the activity of the second promoter or 2) decreases the activity of the second promoter.

Embodiments of the claimed invention wherein the coat protein is i) a wild type gene III protein, or ii) a mutant gene III protein with reduced ability to associate with the phage particle.

Application/Control Number: 10/723,981

Art Unit: 1648

For Group II above, the Applicant is further required to elect one of the following species, representing the claimed invention wherein the claimed polynucleotide is a) a phagemid or b) a phage genome.

- 6. The species are independent or distinct but related inventions. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case, each of the claimed species represents a distinct invention from the related species because the various species represents an embodiment with a different design or mode of operation from the related invention. With respect to the phagemids and genomes of Group II, these species have distinct designs (one encodes a complete phage, whereas the other lacks genes for essential phage proteins), and have different modes of operation for the production of progeny phage (one requires the use of a helper phage). The species therefore represent distinct inventions.
- 7. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1 and 29 are generic for Group I; and claims 23 and 26 are generic for Group II.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable

Art Unit: 1648

thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Conclusion

- 8. Because these inventions are distinct for the reasons given above, have acquired different classifications, and because the literature and sequence searches required for any one of the groups is not required for the others, restriction for examination purposes as indicated is proper.
- 9. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In

Application/Control Number: 10/723,981 Page 6

Art Unit: 1648

either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103 (a) of the other invention.

- 10. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zachariah Lucas whose telephone number is 571-272-0905. The examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

L. Lucas 6/23/06